Boehringer Ingelheim's dual agonist drug (a new type of weight-loss medicine) showed patients lost 16.6% of their body weight in a Phase 3 trial (a large test to prove the drug works). The company shared results but did not answer some important questions about safety and how well the drug compares to other weight-loss drugs.

• •Boehringer's dual agonist hit 16.6% weight loss in a Phase 3 trial
• •The drug is a dual agonist (works on two targets at once)
• •Boehringer left key safety and comparison questions unanswered